Neuro-oncology: oligodendroglioma and molecular markers

Lancet Neurology

Volumn 6, Issue 1, 2007, Pages 10-12

  Stupp, Roger ^a   Hegi, Monika E ^a  

^a Department of Neurosurgery   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; GEFITINIB; IMATINIB; LOMUSTINE; MOLECULAR MARKER; PROCARBAZINE; VINCRISTINE;

ADJUVANT THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; CYTOGENETICS; DNA DAMAGE; GENE DELETION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; OLIGODENDROGLIOMA; ONCOLOGY; PRIORITY JOURNAL; PROGNOSIS;

EID: 33845306505     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(06)70663-9     Document Type: Note

References (7)

1. van den Bent M., Carpentier A., Brandes A., et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer Phase III Trial. J Clin Oncol 24 (2006) 2715-2722
2. Cairncross G., Berkey B., Shaw E., et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24 (2006) 2707-2714
3. Jenkins R., Blair H., Ballman K., et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66 (2006) 9852-9861
4. Griffin C., Burger P., Morsberger L., et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 65 (2006) 988-994
5. Mellinghoff I., Wang M., Vivanco I., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353 (2005) 2012-2024
6. Lassman A., Rossi M., Razier J., et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 11 (2005) 7841-7850
7. Bao S., Wu Q., McLendon R., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006). published online Oct 18. DOI:10.1038/nature05236